SBIR Phase I: Humanized Mouse Ig system employing BAC

SBIR 第一阶段：采用 BAC 的人源化小鼠 Ig 系统

• 批准号: 0739548
• 负责人: Hiroaki Shizuya
• 金额: $ 10万
• 依托单位: Aliva Biopharmaceuticals
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0739548&HistoricalAwards=false
• 关键词: SBIR; Phase; Humanized; Mouse; Ig

This Small Business Innovation Research (SBIR) Phase I research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required.The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

这项小企业创新研究（SBIR）一期研究项目旨在将整个人类免疫球蛋白位点引入小鼠体内，以便随后从杂交瘤中产生完全人源化的单克隆抗体。针对细胞表面蛋白的单克隆抗体目前被用于各种临床适应症，包括癌症和自身免疫。它们的结合亲和性和特异性使其成为治疗多种需要特异性靶向的疾病的最重要的治疗模式之一。目前的技术是基于一个系统，其中只有80%的免疫球蛋白位点已经人源化。用人类基因替换剩余的小鼠基因将提高产生的抗体的质量和多样性，因此，这将是对这一重要治疗方式的重要贡献。